Latest news with #Isomorphic
Express Tribune
07-07-2025
- Business
- Express Tribune
Isomorphic Labs, Google-backed, to launch human trials for AI-designed drugs
Alphabet's drug discovery arm, Isomorphic Labs, is preparing to enter a new chapter in its ambitious efforts to reshape medicine through artificial intelligence, with its first human clinical trials now on the horizon. Colin Murdoch, the company's president and also Google DeepMind's chief business officer, confirmed to Fortune that trials for AI-designed drugs could begin in the near future. 'We're staffing up now. We're getting very close,' he said during an interview in Paris. The London-based firm, spun out of DeepMind in 2021, was established off the back of AlphaFold, the AI system that stunned scientists by predicting protein structures with remarkable accuracy. That success laid the foundation for a broader mission: to use AI to design new drugs faster, cheaper and with a higher chance of clinical success. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said. 'That's happening right now.' The company was born from one of DeepMind's most celebrated breakthroughs: AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. — FORTUNE (@FortuneMagazine) July 6, 2025 After several years of building infrastructure and refining its approach, Isomorphic is now transitioning from early-stage discovery into clinical development. According to Murdoch, 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings.' AlphaFold's evolution from predicting single protein structures to modelling interactions between proteins, DNA and drug molecules has proven critical to that progress. It has enabled researchers to approach drug design with greater precision, a shift Murdoch believes will help unlock an era of AI-driven breakthroughs in medicine. 'This was the inspiration for Isomorphic Labs,' he said. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' Isomorphic Labs is reimagining drug discovery with the power of AI, and we're scaling our ML team to support the rapid growth of our best-in-class AI models. Heading to ICML and want to find out more? Register to connect with some of our ML team at ICML between 13-19 July:… — Isomorphic Labs (@IsomorphicLabs) July 3, 2025 The company's ambitions are matched by growing financial and industry support. In April 2025, Isomorphic raised $600 million in its first-ever external funding round, led by Thrive Capital. That followed major research agreements signed the previous year with pharmaceutical giants Novartis and Eli Lilly. Under those partnerships, Isomorphic contributes to existing drug pipelines while also developing internal candidates in areas such as oncology and immunology. The aim is to license those compounds once early trial phases are complete. 'We identify an unmet need, and we start our own drug design programs,' Murdoch said. 'We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress.' Traditional drug development remains an expensive and risky process, with costs running into the millions and success rates in early trials often as low as 10%. > Isomorphic Labs is preparing to launch human trials of AI-designed drugs. > Mission: faster, cheaper, more accurate drug discovery using AI. AI will make the world a better place. One day, it might cure every disease and that future is got closer than we think. — AshutoshShrivastava (@ai_for_success) July 7, 2025 Murdoch believes Isomorphic's hybrid model, combining AI with pharma expertise, could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he said. Murdoch envisions a future where AI models could generate effective drug designs at the click of a button. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' he said. 'All powered by these amazing AI tools.'
Boston Globe
17-06-2025
- Business
- Boston Globe
Isomorphic Labs sets up US presence in Cambridge, with an eye on clinical trials
After developing AlphaFold into a drug design platform, the company has entered the era where it is progressing some of those AI-enabled drug candidates toward clinical trials — and to do that, it needs a footprint in the United States. Isomorphic's move comes during a particularly turbulent period for the Advertisement Its first hire in Cambridge is Ben Wolf, who will work from the new office as the company's chief medical officer to build Isomorphic's clinical development team. Wolf was most recently CMO at Relay Therapeutics, whose cancer drug targets have been informed by computational discovery methods. At the end of March, Isomorphic Labs announced a Advertisement 'We're advancing quickly towards the clinic,' said Murdoch. 'As you think about the initial focus of the team in Boston and hiring of Ben, it hits squarely in that second bracket.' Earlier this year, Isomorphic announced development partnerships with US-based Eli Lilly and Switzerland-based Novartis worth $82.5 million up front, with nearly $3 billion in potential value. It also has internal assets in development in oncology and immunology. 'Whether they're headquartered in Boston or not, they've got a strong presence there, so it's helpful to be close to our partners,' said Murdoch, who declined to project clinical timelines for any of the drug candidates. Isomorphic's new office — which has yet to find a permanent home — comes at a The Cambridge office will start small, with up to a dozen employees focused on getting trials off the ground. That's less than a tenth of Isomorphic's total headcount, with about 200 employees concentrated in a central London office and to a smaller extent, in a newer office in Lausanne, Switzerland. Later on, the Cambridge office plans to recruit in other areas — including medicinal chemistry, machine learning, and computational biology — as it continues developing its drug engines. Earlier iterations focused on small molecule drugs, the target of Isomorphic's current pharma partnerships, but the company has expanded to biologics. 'Technically, the platform models everything in terms of atoms,' said Murdoch. 'Biologics and small molecules look pretty much the same when you look at them at that level.' Advertisement Despite Wolf's clinical development expertise, Murdoch said the chief medical officer would also be involved in moving Isomorphic's drug engine forward. 'It sounds a bit out of sequence, because you would normally think about it as a linear process,' he said. But 'in the end, what we're trying to do is create drugs that do work in humans in the clinic. So why not bring forward those insights at the beginning?'
Yahoo
01-04-2025
- Business
- Yahoo
Demis Hassabis on Isomorphic's $600 million raise, AI, and healthcare's future
What if it's not "just a game"? In AI, games are more than just fun—they can reconceive what's possible. Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, knows this firsthand. In 2016, after AlphaGo—the AI program developed to play the ancient Chinese game of Go—defeated world champion Lee Sedol, Hassabis saw a new horizon for AI. The victory wasn't just about beating an 18-time international champion, it was a demonstration of AI's ability to 'think' creatively. "Famously, move 37 of game two in that big challenge match was a move never seen before," Hassabis told Fortune. "That showed some form of originality and creativity, and the kind of new system-generated ideas that would be really useful in science and medicine. I'd been waiting not only for us to crack Go at the world champion level, but for the system to be able to invent new strategies. So, when AlphaGo did both those things, that's when I knew we were ready to take on something like protein-folding." At Google DeepMind, Hassabis and John M. Jumper led the development of AlphaFold, an AI system that predicts protein structures—a feat scientists had been trying to achieve for decades. This groundbreaking achievement won them the 2024 Nobel Prize in Chemistry. (Hassabis cofounded DeepMind with Mustafa Suleyman and Shane Legg, and it was acquired by Google in 2014.) AlphaFold's success would pave the way for Isomorphic Labs, a spinoff focused on AI-driven drug discovery. Isomorphic was founded in 2021, but it wasn't until yesterday that the company announced its first external funding—a $600 million round, led by Thrive Capital with participation from GV. The company has existing partnerships with pharma giants Novartis and Eli Lilly, which help (among other things) deliver a vital piece in Isomorphic's pursuit—data. "You need data for any AI model," said Hassabis. "I think AlphaFold 2 showed there's a lot more one can squeeze out of existing data, if you really, really try, and you're really innovative on the architecture and algorithm side." So, Hassabis's approach to data is multi-dimensional, spanning multiple sources, including public and purchasable datasets, partner-specific data, and internal data garnered from real-world collection. In short, there's a lot of data out there, and now it's time to figure out how to best use it. "We still need better tools to understand biology," said Krishna Yeshwant, GV managing partner. "We need ways to make our whole system work better…I do think there's a real role for machine learning in figuring out biology, figuring out targets, figuring out how we're going to be able to drug them in unique ways." To date, Isomorphic has been cautious about disclosing the diseases it's targeting, though Hassabis offered some color—broadly, oncology and immunology are in the company's sights. The idea is to start by tackling diseases with challenging chemistry problems, but where we fundamentally understand how the disease works. (Comparatively, Hassabis's wife studies Alzheimer's, which he says has too many unknowns to be a target off the bat.) "Isomorphic is going to take all these processes that happen physically and represent them computationally," said Vince Hankes, partner at Thrive Capital. "It'll radically change the entire industry, where you'll look back and it seems obvious. Imagine building an airplane without CAD, doing all the drawings and simulation by hand. We'd never conceive of doing that today, nor would you want to fly in an airplane built by hand versus built by a computer. It'll be the same thing with drug discovery." The history of medicine is gnarly, filled with practices we can no longer fathom, let alone imagine being standard. Think: lobotomies, bloodletting, and rotational therapy—the Victorian belief that if you twirl a patient vigorously in a suspended chair, it could cure mental illness. For Hassabis, success for Isomorphic is nothing short of curing all diseases, creating a new normal. "To be clear, modern medicine has done incredible things, but we need a lot more of it," said Hassabis. "Before penicillin and antibiotics, people could die from a scratch, right? They'd get infected and that was it. Child mortality was massive, because children could die from earaches. Now, we take it for granted. We give them some antibiotics, and they're fine, without a second thought…In another 10 to 20 years, I want to look back at heart attacks or brain aneurysms and say: 'Wow, it's crazy people used to die from that, we can detect it now. Or, with cancer, we can detect it early and deal with it.' It'll be like taking an antibiotic, where it'll be so matter-of-fact. It won't seem extraordinary anymore." Isomorphic's name is drawn from Ancient Greek, a scientific term that references disparate things with the same structure. Hassabis's ambition is grand, but it's also a reminder that something seemingly small can spark seismic change—just like a series of Go games have a throughline to a possible revolution in drug discovery. The largest funding round ever…Yesterday, OpenAI announced it raised $40 billion at a $300 billion valuation. According to CNBC, $30 billion came from round leader SoftBank, while $10 billion came from a group of investors that included Microsoft, Coatue, Altimeter, and Thrive. (Notably, Hankes is Thrive's OpenAI investor, along with firm founder Josh Kushner.) OpenAI's valuation is now on par with ByteDance, and is only surpassed in valuation by SpaceX. See you tomorrow, Allie GarfinkleX: @agarfinksEmail: a deal for the Term Sheet newsletter here. Nina Ajemian curated the deals section of today's newsletter. Subscribe here. This story was originally featured on Sign in to access your portfolio
New York Times
31-03-2025
- Business
- New York Times
Isomorphic Labs, Google's A.I. Drug Business, Raises Money From Thrive
Over the last 12 months, Google's efforts to use artificial intelligence to accelerate drug design have achieved breakthroughs in mimicking human biology and won its top scientists the Nobel Prize in Chemistry. Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor. Isomorphic plans to announce on Monday that it has raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI. GV, Google's venture capital arm, and Alphabet, Google's parent company, also invested. The announcement underscores Google's ambitions for Isomorphic, which was spun out of the company's DeepMind lab to focus on drugs discovery. It is built on software that DeepMind, a central intelligence lab in London, has developed. That includes AlphaFold, which can predict the structure of millions of proteins and more. AlphaFold, which now in its third iteration can predict the complex behavior of DNA and RNA, has promised to slash the development time of new drugs. Such is its promise that Demis Hassabis, a co-founder of Isomorphic and DeepMind, and John M. Jumper, a DeepMind researcher, shared half of the Nobel in chemistry last year. The goal, according to Mr. Hassabis, is to eventually conduct most of the drug discovery process via computers, rather than traditional labs that require biological materials, strict safety requirements — and lots of time. Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times. Thank you for your patience while we verify access. Already a subscriber? Log in. Want all of The Times? Subscribe.
